bioMerieux Acquires Culture Media Specialist PML Microbiologicals Reinforcing Position in the North American Microbiology Market
Founded in 1969, PML has 205 employees with 2007 sales of $24 million. Thecompany has an extensive range of products for use in the clinical andpharmaceutical industries, holding proprietary technologies for innovativeculture media. PML specializes in reagents, including prepared culture media(PPM) for sterility testing and environmental monitoring, as well as controlorganisms, which are complementary to bioMerieux's offering.
The acquisition will enable bioMerieux to become a leading provider in theU.S. of microbiology testing solutions for pharmaceutical companies. Inaddition, bioMerieux will enter the North American clinical PPM market,becoming the number one PPM provider for clinical applications in Canada.
"This new acquisition, our sixth in two years, reinforces the NorthAmerican market position of bioMerieux's core business, microbiology,"declared Stephane Bancel, Chief Executive Officer of bioMerieux. "In thecurrent challenging economic context, we are pleased to add anotherreagent-only business to our portfolio that will boost bioMerieux's recurringsales."
"The PML acquisition brings to our customers in the pharmaceuticalindustry an enhanced range of high performance, innovative solutions for thecontrol of their manufacturing environment and products," added AlexandreMerieux, Corporate Vice President, Industrial Microbiology.
PML's sites in Portland and Toronto will join bioMerieux's worldwidenetwork of culture media production centers with its main site in Craponne(France) and regional facilities in Lombard, Illinois (United States), Madrid(Spain), Basingstoke (England), Brisbane (Australia) and Rio de Janeiro(Brazil).
bioMerieux purchased 100% of PML Microbiologicals' shares from theprivately held Pelican Life Sciences Group, based in San Diego, California(U.S.A.) for the sum of $29.6 million.
Advancing Diagnostics to Improve Public Health
A world leader in the field of in vitro diagnostics for 45 years,bioMerieux is present in more than 150 countries through 39 subsidiaries and alarge network of distributors. In 2007, revenues reached euro 1.063 billionwith 84% of sales outside of France.
bioMerieux provides diagnostic solutions (reagents, instruments, software)which determine the source of disease and contamination to improve patienthealth and ensure consumer safety. Its products are used for diagnosinginfectious diseases and providing high medical value results forcardiovascular emergencies and cancer screening and monitoring. They are alsoused for detecting microorganisms in agri-food, pharmaceutical and cosmeticproducts. bioMerieux is listed on the NYSE Euronext Paris market(Code: BIM - Code ISIN: FR0010096479). Other information can be found athttp://www.biomerieux.com.
You May Also Like